Breast Cancer Start-up Challenge
Connect with Us
  • Winning Teams
  • Startups Launched
  • Phases
    • Start-up Phase
    • Eligibility & Rules
  • Resources
    • Inventions >
      • 1 Diagnostic from biopsies with software analysis
      • 2 Immunotherapy Using Modified Self Tumor Cells
      • 3 Combination of Tissue Reconstruction and Recurrence Prevention
      • 4 Human monoclonal Antibody Based Cancer Therapies
      • 5 Immunotherapy Using Granulysin Activated Monocytes
      • 6 Anti-cancer Toxin
      • 7 Versatile Delivery Method for Cancer Therapeutics
      • 8 Genomic Based Diagnostic Assay
      • 9 Tissue-based Diagnostic Assay
      • 10 Diagnostic Kit for Therapy Benefit Prediction
    • Seed Funders
  • Media
    • News and Past Events
  • Team Blogs
  • Teams
    • Teams Accepted
    • Core Team
    • Judges
    • Challenge Supporters
  • Contact Us
U.S. Patent Allowed - it has been determined that it is “allowed”, meaning it is intended to issue but has not yet been issued or granted.  The NIH will get a notice of allowance once the office actions have all been completed and the USPTO has determined the patent is “issuable."  At that point, the NIH will have to pay the issue fees in order for them to issue the patent.  Sometimes, although rarely, the patent will be abandoned at that point and the fees will be foregone.  In this case, the status cannot be "issued" because it does not have a patent number yet and the issue fees had not yet been paid.
The Center for Advancing Innovation, INC 2013